The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Open accessAbstract
BACKGROUND: The use of available antiviral agents for the prevention of cytomegalovirus (CMV) disease is limited by frequent toxic effects and the emergence of resistance. CMX001 has potent in vitro activity against CMV and other double-stranded DNA viruses. We evaluated the safety and anti-CMV activity of CMX001 in patients who had undergone allogeneic hematopoietic-cell transplantation. METHODS: From December 2009 through June 2011, a total of 230 patients with data that could be evaluated were enrolled in the study. We randomly assigned these adult CMV-seropositive transplant recipients from 27 centers to oral administration of CMX001 or placebo. Patients were assigned in a 3:1 ratio to five sequential study cohorts according to a dose-escalating, double-blind design. Randomization was stratified according to the presence or absence of acute graft-versus-host disease and CMV DNA in plasma. Patients received the study drug after engraftment for 9 to 11 weeks, until week 13 after transplantation. Polymerase-chain-reaction analysis of CMV DNA in plasma was performed weekly. Patients in whom CMV DNA was detected at a level that required treatment discontinued the study drug and received preemptive treatment against CMV infection. The primary end point was a CMV event, defined as CMV disease or a plasma CMV DNA level greater than 200 copies per milliliter when the study drug was discontinued. The analysis was conducted in the intention-to-treat population. RESULTS: The incidence of CMV events was significantly lower among patients who received CMX001 at a dose of 100 mg twice weekly than among patients who received placebo (10% vs. 37%; risk difference, -27 percentage points; 95% confidence interval, -42 to -12; P=0.002). Diarrhea was the most common adverse event in patients receiving CMX001 at doses of 200 mg weekly or higher and was dose-limiting at 200 mg twice weekly. Myelosuppression and nephrotoxicity were not observed. CONCLUSIONS: Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced the incidence of CMV events in recipients of hematopoietic-cell transplants. Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly. (Funded by Chimerix; CMX001-201 ClinicalTrials.gov number, NCT00942305.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Ljungman, P., Griffiths, P., & Paya, C. (2002) · Clinical Infectious Diseases · doi:10.1086/339329 · Cited by 1,234
Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant
Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., & Meyers†, J. D. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00003 · Cited by 650
Antiviral Drug Resistance of Human Cytomegalovirus
Lurain, N. S., & Chou, S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-10 · Cited by 596
Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R., & Zaia, J. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00287-8 · Cited by 431
Self-citationMarty, F. M., Ljungman, P., Papanicolaou, G. A., Winston, D. J., Chemaly, R. F., Strasfeld, L., Young, J.-A. H., Rodriguez, T., Maertens, J., Schmitt, M., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70024-x · Cited by 350
Self-citationHostetler, K. Y. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.01.005 · Cited by 244
Painter, W., Robertson, A. T., Trost, L. C., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05983-11 · Cited by 177
Self-citationCiesla, S. L., Trahan, J., Wan, W. B., Beadle, J. R., Aldern, K. A., Painter, G. R., & Hostetler, K. Y. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00110-4 · Cited by 176
Green, M. L., Leisenring, W., Stachel, D., Pergam, S. A., Sandmaier, B. M., Wald, A., Corey, L., & Boeckh, M. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.05.015 · Cited by 165
Self-citationMarty, F. M., Porter, J., Browne, S., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069294 · Cited by 142
Self-citationWilliams-Aziz, S. L., Hartline, C. B., Harden, E. A., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3724-3733.2005 · Cited by 131
Paolino, K., Sande, J. E., Perez‐Albuerne, E. D., Loechelt, B. J., JANTAUSCH, B. A., Painter, W., Anderson, M., Tippin, T., Lanier, E. R., Fry, T. J., et al. (2010) · Journal of Clinical Virology · doi:10.1016/j.jcv.2010.10.016 · Cited by 92
Design and development of oral drugs for the prophylaxis and treatment of smallpox infection
Painter, G. R., & Hostetler, K. Y. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.06.008 · Cited by 80
Quenelle, D. C., Lampert, B. M., Collins, D. J., Rice, T., Painter, G. R., & Kern, E. R. (2010) · The Journal of Infectious Diseases · doi:10.1086/656717 · Cited by 75
Quenelle, D. C., Collins, D. J., Herrod, B. P., Keith, K. A., Trahan, J., Beadle, J. R., Hostetler, K. Y., & Kern, E. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00184-07 · Cited by 39
Cited by
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P., Chemaly, R. F., Maertens, J., Dadwal, S. S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,238
Self-citationKotton, C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov, L., & Humar, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002191 · Cited by 1,152
Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., Razonable, R. R., Miller, V., & Griffiths, P. D. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw668 · Cited by 955
Self-citationAdenovirus Infections in Immunocompetent and Immunocompromised Patients
Lion, T. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00116-13 · Cited by 861
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Metadata
- Authors
- Marty, F. M., Winston, D. J., Rowley, S. D., Vance, E., Papanicolaou, G. A., Mullane, K. M., Brundage, T. M., Robertson, A. T., Godkin, S., Momméja-Marin, H., & Boeckh, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-26
- Volume
- 369
- Issue
- 13
- Pages
- 1227-1236
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2312658128
- Cited by
- 374
- References
- 17
- FWCI
- 34.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.